SEC Filing Summary: AcelRx Pharmaceuticals, Inc. 10-Q
Reporting period: Quarter ended June 30, 2017; filed August 1, 2017. The request metadata names TALPHERA, INC., but the filing identifies the registrant as AcelRx Pharmaceuticals, Inc. The summary below covers the filing provided.
Business context and reporting period
AcelRx is a specialty pharmaceutical company developing sublingual sufentanil therapies for acute pain. Its principal candidates are DSUVIA (30 mcg, administered by a healthcare professional) and ZALVISO (15 mcg, patient-controlled system). ZALVISO was approved in Europe and commercialized by partner Grünenthal; neither product had U.S. approval at the reporting date.
Financial results and liquidity
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Total revenue | $2.7m | $4.5m | $5.8m | $7.6m |
| Operating expenses | $12.6m | $12.9m | $27.8m | $24.4m |
| Operating loss | $9.9m | $8.3m | $22.0m | $16.8m |
| Net loss | $13.1m | $11.1m | $28.6m | $22.1m |
| Net loss per share | $0.29 | $0.24 | $0.63 | $0.49 |
- Q2 collaboration revenue was $2.2m, while contract and other revenue, primarily DoD contract work, was $0.5m. For the first half, these were $5.2m and $0.5m, respectively.
- Q2 cost of goods sold was $3.5m, exceeding revenue; management expects negative gross margins on ZALVISO deliveries for the foreseeable future. A $0.4m inventory impairment was recorded in Q2, primarily on ZALVISO materials and related purchase commitments.
- Six-month operating cash use was $16.3m, versus $14.5m in 2016. Cash and cash equivalents were $62.1m at June 30, down from $80.3m at December 31, 2016. The filing reports no separate cash-flow forecast by quarter.
- Debt under the Hercules loan was $22.0m accrued at June 30. Total liabilities were $109.8m, including a $78.1m liability related to the sale of future royalties; stockholders’ deficit was $31.6m.
- Management said available capital was expected to fund operations through at least the third quarter of 2018, while warning that additional capital would likely be needed thereafter and might not be available on acceptable terms.
Material changes versus the prior comparable period
- Q2 revenue declined 41% year over year, mainly because DoD contract revenue fell to $0.5m from $3.2m; Grünenthal collaboration revenue increased to $2.2m from $1.3m. First-half revenue fell 24%.
- Net loss widened by $2.0m in Q2 and $6.5m for the first half. First-half R&D expense rose 13% to $11.8m, as higher ZALVISO study costs more than offset lower DSUVIA spending; G&A increased 12% to $8.3m.
- On March 2, 2017, AcelRx refinanced its Hercules borrowing, drawing approximately $20.5m to repay the prior loan. The new agreement provides up to $10m in additional borrowing subject to DSUVIA FDA approval by December 31, 2017 and lender investment committee approval. Scheduled maturity is March 2020, with potential extensions if specified milestones are met.
- Property and equipment purchases were $2.0m in the first half, compared with $0.3m in 2016; operating cash use increased by $1.8m.
Outlook, commentary, risks and unusual items
- DSUVIA’s U.S. NDA had been accepted for review; the PDUFA review goal date was October 12, 2017. FDA advised in June that it would not hold the anticipated joint advisory committee meeting. The European ARX-04 application was under review, with a CHMP opinion expected in the first half of 2018.
- AcelRx expected to resubmit the ZALVISO U.S. NDA by year-end 2017. The filing reports that top-line results from the IAP312 study were announced in August 2017, after quarter-end: device errors occurred in 2.2% of patients, below the study’s 5% threshold, with no related overdosing. FDA acceptance of the results and approval remained uncertain.
- The DoD contract, initially up to $17m, was extended through February 28, 2018 for packaging changes, stability testing and potential FDA meeting preparation. If DSUVIA is approved, DoD may purchase 112,000 commercial units.
- Management expected approximately $11m of non-cash interest expense from the royalty monetization liability in 2017. The liability is imputed at an estimated effective annual rate of about 14%, subject to revision based on expected royalty and milestone receipts.
- Key risks include regulatory rejection, delay or label restrictions for opioid products; additional studies or REMS requirements; limited early ZALVISO sales and negative product margins; reliance on Grünenthal and external manufacturers; and the need for further financing. Management noted that opioid-policy scrutiny was increasing and that neither candidate had an abuse-deterrent formulation.
- AcelRx reported no material legal proceedings and concluded disclosure controls were effective. It also extended its Redwood City lease for 72 months beginning February 2018, at annual rent of approximately $1.2m plus specified operating expenses.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is for AcelRx Pharmaceuticals, Inc., not TALPHERA, INC.
- Check the subsequent FDA outcome and any additional requirements for the DSUVIA NDA, whose review goal date was October 12, 2017.
- Verify whether the IAP312 results supported ZALVISO NDA resubmission and how the FDA assessed device errors and dropped tablets.
- Monitor cash burn, financing needs, and whether the stated runway through at least Q3 2018 remained achievable.
- Track Grünenthal’s ZALVISO sales, AcelRx’s net margins on supply, and the effect of the PDL royalty monetization on future receipts.
- Review debt repayment terms, conditional access to the additional Hercules tranche, and the royalty liability’s estimated interest and repayment trajectory.